scholarly journals Clinical and metabolic effects of the original iodine metabolic composition in the experiment on calves

2021 ◽  
Vol 285 ◽  
pp. 04003
Author(s):  
A. A. Evglevskiy ◽  
O.M. Shvets ◽  
T.I. Mikhaleva
Keyword(s):  
Succinic Acid ◽  
Iodine Deficiency ◽  
Metabolic Disorders ◽  
Sodium Succinate ◽  
Clinical Signs ◽  
Metabolic Effects ◽  
Polymer Complex ◽  
Thyroid Status ◽  
Combined Action ◽  
Infective Activity

The article provides a theoretical justification for the development of a complex iodine metabolic composition based on an iodinepolymer complex (iodinol) and succinic acid. The research on the effectiveness of the proposed composition for the correction of energymetabolic disorders in calves with severe iodine deficiency was carried out. The objects of research were calves with clinical signs of iodine deficiency and pronounced energy metabolic disorders. During the experiment, it was found that the test calves showed a marked improvement in the clinical condition. The thyroid status normalized, the total protein and glucose indicators approached the physiological norm, and the reserve alkalinity of the blood increased. The energetic metabolic effect was due to the combined action of iodinol and succinic acid. The obtained results indicate the opening prospect of an injection method for the use of an iodine polymer complex based on iodine-iodide with polyvinyl alcohol (iodinol) in combination with sodium succinate, not only as an effective approach to cupping and eliminating the iodine deficiency symptoms, but also as an active energy-metabolic drug with a potentially high anti-infective activity.

Assessment of the quality of life in the treatment approaches of patients with the comorbid course of arterial hypertension and metabolic disorders aimed at reducing cardiovascular risk

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
V Zlatkina ◽  
V Shkapo ◽  
A Nesen ◽  
T Starchenko
Keyword(s):  
Quality Of Life ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Arterial Hypertension ◽  
Metabolic Disorders ◽  
Clinical Signs ◽  
Blood Analysis ◽  
Sf 36 ◽  
Artery Disease

Abstract Funding Acknowledgements Type of funding sources: None. Introduction. Cardiovascular diseases (CVD) remain the leading cause of premature death worldwide. According to epidemiological studies CVD prevention is highly effective. A 50% reduction in mortality from coronary artery disease (CAD) is associated with exposure to risk factors and only 40% with improved treatment. Purpose.  To assess the quality of life (QOL) in patients with arterial hypertension (AH) and metabolic disorders, to establish its impact on therapy effectiveness. We examined 280 patients with AH and comorbidity - 171 women and 109 men aged 45-75 years. Along with AH, all patients had comorbidities: 72.6 % suffered from coronary artery disease (CAD), 10.5% after myocardial infarction (MI), 35 % had clinical signs of heart failure (HF), 22, 1% - type 2 diabetes mellitus (t2DM), 27.4% - chronic kidney disease (CKD). Methods. Anthropometry, blood pressure (BP) measurement, immunoassay (C-reactive protein), biochemical blood analysis (lipid, carbohydrate metabolism parameters, QOL determination (questionnaire Sf-36). Results. In patients with comorbidity of pathologies (presence of AH, t2DM, CKD, CAD, obesity), there was a decrease in assessments in almost all indicators of QOL, and especially significant limitations in the performance of daily activities due to both physical and mental state. Conclusion. The degree of AH in patients with t2DM decreased QOL of physical activity, role-physical functioning, pain and general health, reflecting physical health, as well as mental health, including vitality, social activity, role emotional functioning. T2DM in patients with AH significantly worsens QOL of this category of patients as in physical component summary and mental component summary. The indicators of QOL are significantly affected by the duration of t2DM, as well as the degree of compensation. Achievement of the target BP levels in patients with AH with t2DM shows an improvement in a number of QOL parameters and makes it possible to recommend the Sf-36 questionnaire as a criterion for the effectiveness of the therapy.

A Suggestion for an Effective Use of a Computer-aided Diagnosis System in Screening for Hyperthyroidism

1977 ◽  
Vol 16 (02) ◽  
pp. 93-95 ◽  
Author(s):  
A. Alpérovitch ◽  
P. Fragu
Keyword(s):  
Clinical Signs ◽  
Test Sample ◽  
Bayes Theorem ◽  
Computer Assisted ◽  
Thyroid Status ◽  
Screening Strategies ◽  
Computer Aided ◽  
Using Data ◽  
Effective Use ◽  
Aided Diagnosis

A computer-assisted program for diagnosing hyperthyroidism, specially devoted to the screening of functional thyroid status, has been written using data provided by 359 patients, 282 euthyroid and 77 hyperthyroid. The model is based on Bayes’ theorem.Using only 9 clinical signs and the free thyroxin index, the program achieved, on a test-sample of 117 new patients, an overall accuracy of 90% ; 10% of the cases were in the zone of uncertainty, and none was misdiagnosed.Different screening strategies are examined and their results discussed.

scholarly journals Proposal of an Algorithm to Early Detect Attenuated Type I Mucopolysaccharidosis (MPS Ia) among Children with Growth Abnormalities

Medicina ◽  
2022 ◽  
Vol 58 (1) ◽  
pp. 97
Author(s):  
Federico Baronio ◽  
Stefano Zucchini ◽  
Francesco Zulian ◽  
Mariacarolina Salerno ◽  
Rossella Parini ◽  
...  
Keyword(s):  
Short Stature ◽  
Metabolic Disorders ◽  
Clinical Presentation ◽  
Diagnostic Delay ◽  
Clinical Signs ◽  
Clinical Approach ◽  
Type I ◽  
Mucopolysaccharidosis Type I ◽  
Stunted Growth ◽  
Growth Abnormalities

Background and Objectives: Diagnostic delay is common in attenuated Mucopolysaccharidosis Type I (MPS Ia) due to the rarity of the disease and the variability of clinical presentation. Short stature and impaired growth velocity are frequent findings in MPS Ia, but they rarely raise suspicion as paediatric endocrinologists are generally poorly trained to detect earlier and milder clinical signs of this condition. Materials and Methods: Following a consensus-based methodology, a multidisciplinary panel including paediatric endocrinologists, paediatricians with expertise in metabolic disorders, radiologists, and rheumatologists shared their experience on a possible clinical approach to the diagnosis of MPS Ia in children with short stature or stunted growth. Results: The result was the formation of an algorithm that illustrates how to raise the suspicion of MPS Ia in a patient older than 5 years with short stature and suggestive clinical signs. Conclusion: The proposed algorithm may represent a useful tool to improve the awareness of paediatric endocrinologists and reduce the diagnostic delay for patients with MPS Ia.

scholarly journals THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors

2021 ◽  
Vol 184 (1) ◽  
pp. R29-R40
Author(s):  
Poupak Fallahi ◽  
Silvia Martina Ferrari ◽  
Giusy Elia ◽  
Francesca Ragusa ◽  
Sabrina Rosaria Paparo ◽  
...  
Keyword(s):  
Metabolic Disorders ◽  
Kinase Inhibitors ◽  
Thyroid Stimulating Hormone ◽  
Term Treatment ◽  
Metabolic Effects ◽  
Glucose Levels ◽  
Antihyperglycemic Therapy ◽  
Long Term Treatment ◽  
Developmental Capacity ◽  
Distant Spread

Tyrosine kinase inhibitors (TKIs) are emerging as potentially effective options in the treatment of cancer, acting on the pathways involved in growth, avoidance of apoptosis, invasiveness, angiogenesis, and local and distant spread. TKIs induce significant adverse effects, that can negatively affect patients’ quality of life. The most common adverse events (AEs) include fatigue, hand–foot skin reaction, decreased appetite, nausea, diarrhea, hypertension, vomiting, weight loss, endocrinopaties and metabolic disorders. Patients in therapy with TKIs can develop endocrine-metabolic disorders, including dyslipidemia (~50%), diabetes (~15–40%), and dysthyroidism (~20%). In some cases, patients show an improved glycemia or hypoglycemia. The effects of TKIs on adrenal or gonadal function are still not completely known. It was shown a higher prevalence of subclinical hypocortisolism in patients treated with imatinib, while an increase of cortisol was reported in patients receiving vandetanib. Long-term treatment with imatinib could impact significantly the ovarian reserve and embryo developmental capacity. It is important to evaluate patients, measure glucose levels, and manage hyperglycemia. Mild treatment-related hyperglycemia can be controlled modifying the diet and with exercise, while grade 3 and 4 hyperglycemia can lead to dose reductions and/or oral antihyperglycemic therapy. Regarding thyroid dysfunctions, it is recommendable to measure the thyroid-stimulating hormone (TSH)/free thyroxine (FT4) levels before starting the therapy, and every 3–4 weeks during the first 6 months as changes in FT4 levels precede the changes in TSH by 3–6 weeks. Additional studies are necessary to definitely clarify the mechanism of TKIs-induced endocrine-metabolic effects.

Lead toxicosis in cats—a review

2003 ◽  
Vol 5 (5) ◽  
pp. 249-255 ◽  
Author(s):  
TE Knight ◽  
MSA Kumar
Keyword(s):  
Diagnostic Tests ◽  
Aminolevulinic Acid ◽  
Clinical Signs ◽  
Body Burden ◽  
Blood Lead ◽  
Good Prognosis ◽  
Metabolic Effects ◽  
Neuronal Necrosis ◽  
The Individual ◽  
High Index Of Suspicion

Although the incidence of lead toxicosis in small animals continues to decrease, it remains a significant malady. We have reviewed the literature of the past 45 years, which revealed 70 cases involving cats. Sources, signs, diagnosis, pathology and treatment of feline lead toxicosis are reviewed. In 84% of these cases the source of lead was old paint usually from home renovation. The most common signs in cats are anorexia, vomiting, and seizures. The younger individuals seem more likely to show CNS signs. Since signs are often vague, lead toxicosis may be significantly under diagnosed in cats. The gold standard of diagnostic tests is blood lead concentration, although it does not necessarily correlate with total body burden of lead or with metabolic effects including clinical signs. Diagnostic tests including erythropoietic protoporphyrin (EPP), urine aminolevulinic acid, and others are discussed. Gross findings on necropsy are few and include a yellow-brown discoloration of the liver often with a nutmeg-like appearance. Histological examination may reveal pathognomonic inclusion bodies in liver and renal tissues. Characteristic histological changes in the CNS include neuronal necrosis and demyelination. Treatment of lead toxicosis in cats, as in any species, involves removing the exposure, decontaminating the individual and the environment, supportive care and chelation therapy. The most recently available chelator is succimer (meso 2,3-dimercaptosuccinic acid). Succimer given orally is well tolerated and has a wide margin of safety. A high index of suspicion of lead toxicosis is warranted in cats since they often present with vague and non-specific signs. With any consistent history owners need to be asked about home renovation. Early diagnosis and treatment affords a good prognosis.

scholarly journals AMPK as a mediator of hormonal signalling

2009 ◽  
Vol 44 (2) ◽  
pp. 87-97 ◽  
Author(s):  
Chung Thong Lim ◽  
Blerina Kola ◽  
Márta Korbonits
Keyword(s):  
Protein Synthesis ◽  
Fatty Acid ◽  
Metabolic Disorders ◽  
Energy Homeostasis ◽  
Metabolic Effects ◽  
Whole Body ◽  
Acid Oxidation ◽  
Treatment Of Obesity ◽  
Amp Activated Protein Kinase ◽  
Hormonal Signalling

AMP-activated protein kinase (AMPK) is a key molecular player in energy homeostasis at both cellular and whole-body levels. AMPK has been shown to mediate the metabolic effects of hormones such as leptin, ghrelin, adiponectin, glucocorticoids and insulin as well as cannabinoids. Generally, activated AMPK stimulates catabolic pathways (glycolysis, fatty acid oxidation and mitochondrial biogenesis) and inhibits anabolic pathways (gluconeogenesis, glycogen, fatty acid and protein synthesis), and has a direct appetite-regulating effect in the hypothalamus. Drugs that activate AMPK, namely metformin and thiazolidinediones, are often used to treat metabolic disorders. Thus, AMPK is now recognised as a potential target for the treatment of obesity and associated co-morbidities.

Polysulfonylamine, XV [1] Synthese von N,N,N′,N′-Tetramesyl-dicarbonsäurediamiden. Cyclisierung von N,N,N′,N′-Tetramesyl-bernsteinsäurediamid zu γ-DimesyIamino-Δβγ-butenolid / Polysulfonylamines, XV [1]. Synthesis of N,N,N′,N′-Tetramesyl Dicarboxylic Diamides. Cyclization of N,N,N′,N′-Tetramesyl Succinic Diamide to γ-Dimesylamino-Δβγ-butenolide

1989 ◽  
Vol 44 (4) ◽  
pp. 465-474 ◽  
Author(s):  
Armand Blaschette ◽  
Karin Linoh ◽  
Dietrich Koch ◽  
Ludger Ernst
Keyword(s):  
Succinic Acid ◽  
Acid Derivative ◽  
Analytical Methods ◽  
Room Temperature ◽  
Chemical Shifts ◽  
Sodium Succinate ◽  
Ring Closure ◽  
Ring Cleavage ◽  
New Compounds ◽  
C Nmr

N, N, N′, N′ -Tetramesyl dicarboxylic diamides Ms2NC(O)-Q-C(O)NMs2 [Q = (CH2)n with n = 0 (2a), 2 (2b), 3 (2c), 4 (2d); Q = o-phenylene (2e)] were prepared by reacting AgNMs2 (1) with the appropriate dicarboxylic dichlorides in acetonitrile at room temperature (2a, 2 c-2e) or at 0 °C (2b), respectively. Under similar conditions, malonic dichloride undergoes an elimination, forming AgCl, HNMs2 and probably polymeric C3O2. At 20 °C in CH3CN, the succinic acid derivative 2b eliminates one mole of HNMs2 and, by ring closure, yields γ-dimesylamino-Δβγ- butenolide (4a), the first example of a stable γ-amino-Δβγ-butenolide. Treatment of 4a with aqueous NaOH results in the formation of NaNMs2 and sodium succinate. Crystalline 4a is thermally stable at 100 °C; no signs of an isomerization 4a → γ-dimesylamino-Δαγ-butenolide could be detected. Unlike the structurally related α-angelicalactone (4c), whose bromination affords the saturated dibromolactone 9 as a mixture of cis- and mws-isom ers, 4a adds bromine (20 °C, CHCl3) under ring cleavage to form BrC(O)CH2CHBrC(O)NMs2 (7). The new compounds 2, 4a and 7 as well as the stereoisomers of 9 were characterized by spectroscopic (1H and 13C NMR, MS, IR) and analytical methods. In order to obtain reference values for the chemical shifts of 7, the following new compounds were prepared: CH3(CH2)2C(O)NMs2 (10c, from 1 and butvryl chloride); CH3CH2CHBrC(O)NMs2 (12c, from 1 and 2-bromobutyryl bromide); C2H5OC(O)CH 2CHBrC(O)NMs2 (13, from 7 with ethanol and from 4a by simultaneous reaction with bromine and ethanol).

Beneficial metabolic effects of methylprednisolone sodium succinate in acute myocardial ischemia

1976 ◽  
Vol 37 (4) ◽  
pp. 557-563 ◽  
Author(s):  
Thomas N. Masters ◽  
Norris B. Harbold ◽  
Donald G. Hall ◽  
Robert D. Jackson ◽  
Donald C. Mullen ◽  
...  
Keyword(s):  
Myocardial Ischemia ◽  
Sodium Succinate ◽  
Acute Myocardial Ischemia ◽  
Metabolic Effects ◽  
Methylprednisolone Sodium Succinate

THYROID FUNCTION TESTS IN ADULTS WITH DOWN'S SYNDROME

1978 ◽  
Vol 88 (1) ◽  
pp. 48-54 ◽  
Author(s):  
S. Korsager ◽  
E. M. Chatham ◽  
H. P. Østergaard Kristensen
Keyword(s):  
Thyroid Function ◽  
Down's Syndrome ◽  
Clinical Signs ◽  
Down’S Syndrome ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Function Tests ◽  
Thyroid Status ◽  
Biochemical Tests ◽  
Old Patients ◽  
Function Tests

ABSTRACT Thyroid status was studied in 24 patients above the age of 40 years with Down's syndrome. Three patients had thyroid function tests indicating hypothyroidism. Eight patients had thyroid autoantibodies in serum and 8 patients had a higher than normal level of thyroid stimulating hormone in serum. None of the patients had figures indicating thyrotoxicosis. None of the patients showed any of the clinical signs usually seen in patients with hypothyroidism. It is concluded that biochemical tests indicating hypothyroidism are much more often seen in patients with Down's syndrome than in normal subjects and that thyroid status should be assessed in old patients with this disease.

Conductance Studies of Aqueous Succinic Acid

1992 ◽  
Vol 47 (3) ◽  
pp. 493-498 ◽  
Author(s):  
Alexander Apelblat ◽  
Josef Barthel
Keyword(s):  
Aqueous Solutions ◽  
Succinic Acid ◽  
Sodium Succinate ◽  
Equilibrium Constants ◽  
Limiting Conductances

Abstract Conductance measurements of aqueous solutions of succinic acid and of di-sodium succinate were performed from 278.15 to 308.15 K and the limiting conductances λ0 (1/2 Succ2- ) are reported. The Waiden product is independent of temperature: λ0(1/2 Succ2-)*η(T) = 0.503 ± 0.001. The salt conductances closely obey the Onsager limiting law. The evaluation of the equilibrium constants for the primary and secondary steps of dissociation, K1 and K2, and the limiting conductances of the hydrosuccinate ion, λ0(HSucc-), are discussed using the Quint and Viallard conductance equation

Sign in / Sign up

Export Citation Format

Share Document